Prevenar 13®

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline, MCM Vaccines B.V.

Conditions

Acellular PertussisBacterial InfectionsDiphtheriaHaemophilus Influenzae Type bHepatitis BNeisseria MeningitidisPoliomyelitisTetanus

Phase 2

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

CompletedNCT01090453

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +4

Start: 2010-05-17End: 2011-10-11Updated: 2018-08-20

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

CompletedNCT01248884

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +3

Start: 2010-12-09End: 2012-01-05Updated: 2018-08-20

Phase 3

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

CompletedNCT01839188

MCM Vaccines B.V.Bacterial Infections, Neisseria Meningitidis, Virus Diseases

Start: 2013-05-01End: 2014-03-19Updated: 2019-02-25

Related Papers

Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).

2017-06-0213 citations

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and<i>Haemophilus influenzae</i>type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed<i>Infanrix hexa</i>

Human Vaccines & Immunotherapeutics2017-03-241 citations

A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4 and 12 months of age.

2014-12-014 citations